Loading patent…
AssigneeBaylor College of Medicine
InventorsLeonid S. Metelitsa, Amy N. Courtney, Xin Xu, Andras Heczey
Estimating the term…
Embodiments of the disclosure encompass methods and compositions related to modified cells and uses thereof, wherein the cells are engineered with respect to expression of B-cell translocation gene 1 (BTG1). In specific embodiments, the engineered cells are utilized for adoptive cell therapy for particular disease states. In some embodiments, the engineered cells are immune cells, such as T cells, having reduced expression of BTG1 and are utilized to enhance therapy for cancer and/or infectious disease. In some embodiments, the engineered cells are cells having increased inducible expression of BTG1 and are utilized for therapy for autoimmune disease. In some embodiments, the expression of BTG1 is increased in endogenous cells in an individual with autoimmune disease.
A method of enhancing cell therapy for an individual, comprising the step of reducing expression and/or activity of B-cell translocation gene 1 (BTG1) in the cells for the cell therapy.
A method of enhancing cell therapy for an individual, comprising the step of reducing expression and/or activity of B-cell translocation gene 1 (BTG1) in the cells, wherein the cells are not T cells.
An engineered non-cancerous cell, said cell engineered to comprise a reduction in expression and/or activity of BTG1, wherein the cell expresses one or more heterologous genes.
An engineered CD8 T cell, CD4 T cell, NKT cell, MAIT cell, γ/δ T cell, Virus-specific T cell, Cytokine-induced killer cell, NK cell, macrophage, or a mixture thereof, said cell engineered to comprise a reduction in expression and/or activity of BTG1.
A method of treating an autoimmune disease in an individual, comprising the step of administering to the individual a therapeutically effective amount of cells comprising an increase in inducible expression and/or activity of BTG1 and/or comprising the step of administering to the individual a therapeutically effective amount of a drug that increases expression and/or activity of BTG1 in endogenous cells of the individual.
An engineered cell, wherein the cell is engineered to have an increase in expression of endogenous BTG1 and/or that comprises a vector that expresses heterologous BTG1.
A method of controlling activity and/or toxicity of a cell therapy, comprising the step of increasing expression and/or activity of BTG1 in the cells of the cell therapy.
Dependencies are inferred from the claim text.